OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody
G Valenzuela, Ronald Jara, Daniel Watterson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 12
G Valenzuela, Ronald Jara, Daniel Watterson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 12
Showing 12 citing articles:
High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
Thomas J. Esparza, Negin P. Martin, George P. Anderson, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 107
Thomas J. Esparza, Negin P. Martin, George P. Anderson, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 107
Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the Human-Animal Interface
Hayden D. Hedman, Eric Krawczyk, Yosra A. Helmy, et al.
Pathogens (2021) Vol. 10, Iss. 2, pp. 180-180
Open Access | Times Cited: 44
Hayden D. Hedman, Eric Krawczyk, Yosra A. Helmy, et al.
Pathogens (2021) Vol. 10, Iss. 2, pp. 180-180
Open Access | Times Cited: 44
An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation
Michael Schoof, Bryan Faust, Reuben A. Saunders, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 47
Michael Schoof, Bryan Faust, Reuben A. Saunders, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 47
Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)
Salma Bessalah, Samira Jebahi, Naceur Mejri, et al.
3 Biotech (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 32
Salma Bessalah, Samira Jebahi, Naceur Mejri, et al.
3 Biotech (2021) Vol. 11, Iss. 2
Open Access | Times Cited: 32
Veterinarians and One Health in the Fight Against Zoonoses Such as COVID-19
Roberta Torres de Melo, D. A. Rossi, Guilherme Paz Monteiro, et al.
Frontiers in Veterinary Science (2020) Vol. 7
Open Access | Times Cited: 22
Roberta Torres de Melo, D. A. Rossi, Guilherme Paz Monteiro, et al.
Frontiers in Veterinary Science (2020) Vol. 7
Open Access | Times Cited: 22
Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review
Muhammad Azharuddin Azali, Salmah Mohamed, Azian Harun, et al.
Journal of Genetic Engineering and Biotechnology (2022) Vol. 20, Iss. 1, pp. 98-98
Open Access | Times Cited: 9
Muhammad Azharuddin Azali, Salmah Mohamed, Azian Harun, et al.
Journal of Genetic Engineering and Biotechnology (2022) Vol. 20, Iss. 1, pp. 98-98
Open Access | Times Cited: 9
High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme
Thomas J. Esparza, Negin P. Martin, George P. Anderson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 10
Thomas J. Esparza, Negin P. Martin, George P. Anderson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 10
Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses
Hui Ting Lim, Boon Hui Kok, Chin Peng Lim, et al.
Biomedical Engineering Advances (2022) Vol. 4, pp. 100054-100054
Open Access | Times Cited: 6
Hui Ting Lim, Boon Hui Kok, Chin Peng Lim, et al.
Biomedical Engineering Advances (2022) Vol. 4, pp. 100054-100054
Open Access | Times Cited: 6
Cellular Immunotherapy and the Lung
Sorcha Daly, Andrew O’Sullivan, Ronan MacLoughlin
Vaccines (2021) Vol. 9, Iss. 9, pp. 1018-1018
Open Access | Times Cited: 7
Sorcha Daly, Andrew O’Sullivan, Ronan MacLoughlin
Vaccines (2021) Vol. 9, Iss. 9, pp. 1018-1018
Open Access | Times Cited: 7
NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response
Teresa R. Wagner, Philipp D. Kaiser, Marius Gramlich, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 5
Teresa R. Wagner, Philipp D. Kaiser, Marius Gramlich, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 5
Serological Profile Of Specific Antibodies Against Dominant Antigens Of SARS-CoV-2 In Chilean COVID-19 Patients.
Karina Cereceda, Roxana González‐Stegmaier, JL. Briones, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 2
Karina Cereceda, Roxana González‐Stegmaier, JL. Briones, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 2
Insights into biological therapeutic strategies for COVID-19
Xiaolong Tian, Li Cheng, Yanling Wu, et al.
Fundamental Research (2021) Vol. 1, Iss. 2, pp. 166-178
Open Access | Times Cited: 2
Xiaolong Tian, Li Cheng, Yanling Wu, et al.
Fundamental Research (2021) Vol. 1, Iss. 2, pp. 166-178
Open Access | Times Cited: 2
